Gland Pharma Ltd stock (INE025W01027): Shares down 31% from 52-week high amid market pressures

Gland Pharma Ltd shares have fallen 31% from their 52-week high of Rs 2,400 to Rs 1,650, driven by broad Indian market corrections, US tariffs announced April 2, 2026, and earnings growth slowdown.

Gland Pharma Ltd shares on the NSE have declined 31% from their 52-week high of Rs 2,400 to Rs 1,650, reflecting broader Indian equity market weakness intensified by a US reciprocal tariff announcement on April 2, 2026, imposing a 26% levy on Indian goods, alongside company-specific earnings deceleration, Univest as of May 2026.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Gland Pharma Ltd
• Sector/industry: Injectables CDMO Pharmaceuticals
• Headquarters/country: India
• Core markets: Global generics, focus on US
• Home exchange/listing venue: NSE (GLAND)
• Trading currency: INR

Gland Pharma Ltd: core business model

Gland Pharma Ltd specializes in the development and manufacture of injectable products as a contract development and manufacturing organization (CDMO) in the pharmaceuticals sector. The company produces a range of sterile injectables, including generics for global markets, with a strong emphasis on complex formulations. Headquartered in Hyderabad, India, it serves major pharmaceutical companies worldwide, company website.

This CDMO model allows Gland Pharma Ltd to leverage its expertise in formulation development and large-scale manufacturing without direct marketing risks. The firm has expanded capacity through investments in new facilities, positioning it as one of the largest injectables players by revenue globally.

Main revenue and product drivers for Gland Pharma Ltd

Gland Pharma Ltd generates primary revenue from generic injectables in areas like paediatrics, cardiovascular, and anti-infectives. Key drivers include long-term supply contracts with US and European partners, where the US market represents significant exposure for US investors tracking global pharma supply chains. Recent data shows the stock at Rs 1,628 with a market cap of 27,291 Cr, Moneyworks4me as of May 2026.

Earnings growth has decelerated from FY23-24 peaks, contributing to valuation de-rating, with the stock applying lower multiples amid cautious sector sentiment.

Industry trends and competitive position

The injectables CDMO sector faces headwinds from US tariff policies and FII selling in Indian markets, yet Gland Pharma Ltd maintains a competitive edge through its scale and US-focused generics pipeline. For US investors, the company's exposure to American pharma buyers underscores its relevance amid supply chain diversification trends.

Conclusion

Gland Pharma Ltd has seen its shares drop significantly amid macro pressures like US tariffs and sector de-rating, with the stock trading around Rs 1,650 after a 31% fall from highs. Investors monitoring Indian pharma names with US ties will watch for earnings recovery signals. The company's CDMO focus offers long-term potential in generics, balanced against current market volatility.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.